NCT00371215

Study of Recombinant Human Thrombin for Bleeding During Autologous Skin Grafting

A Phase 2 Study of Recombinant Human Thrombin (rThrombin) Administered Using a Spray Applicator in Subjects Undergoing Autologous Skin Grafting Following Burn or Traumatic Skin Injury

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: ZymoGenetics · Industry
• Sex: All
• Age: 2 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether rThrombin is safe when used for controlling bleeding during skin graft surgery.

Detailed description

This is a Phase 2 multiple site, single-arm, open-label study designed to evaluate the safety of rThrombin in subjects of age 2 to 75 years who are receiving a partial- or full-thickness autologous sheet or mesh grafts following burn or traumatic skin injury. After establishing eligibility, study participants will be treated with topical spray rThrombin at the skin graft recipient site during autologous skin graft surgery. There will be a 1-month follow-up period after the surgery.

Conditions

• Surgical Hemostasis

Interventions

Type	Name	Description
BIOLOGICAL	rThrombin	1000 U/mL applied topically

Timeline

• Start date: 2006-08-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2006-09-01
• Last updated: 2009-03-09

Locations

1 site across 1 country: United States